title: Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patients.
abstract: BACKGROUND
  Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients.
  
  
  METHODS
  This open-label study compared the HBV dynamics in 85 HIV-HBV-coinfected patients initiating an antiretroviral regimen, either including TDF or associated with ADV. The first 6-month change in viral load was analysed using mixed linear models. The adjusted hazards ratio, comparing the rates of undetectable HBV DNA between treatments, was calculated using a Cox proportional hazard model.
  
  
  RESULTS
  The HBV DNA decay, adjusted for baseline HBV viral load was more pronounced in patients treated with TDF than with ADV at 12 months (66% versus 53%, P=0.0001). Patients in the TDF group presented a steeper slope of decline at 1.1 (95% confidence interval [CI] 0.9-1.3), compared with 0.8 (95% CI 0.6-1.0) in the ADV group (P=0.036). The mean time to HBV DNA undetectability was 19.3 months (95% CI 16.7-22.0) with TDF and 25.9 months (95% CI 21.1-30.7) with ADV. When adjusted for hepatitis B virus e antigen, HBV DNA and alanine aminotransferase levels at baseline, the influence of treatment on time to HBV DNA undetectability remained in favour of TDF versus ADV (hazard ratio=2.79, 95% CI 1.05-7.40, P=0.039)
  
  
  CONCLUSIONS
  TDF influenced more strongly the early-phase HBV DNA kinetics than ADV. This is associated with a sustained antiviral activity in the TDF group, in which patients reached the threshold of HBV undetectability at a faster rate and in a larger proportion than those taking ADV.
authors.affiliation: INSERM UMR-S707, Paris, France. karine.lacombe@sat.aphp.fr
authors.forename: Karine
authors.initials: K
authors.lastname: Lacombe
authors.forename: Joël
authors.initials: J
authors.lastname: Gozlan
authors.forename: Anders
authors.initials: A
authors.lastname: Boyd
authors.forename: Pierre-Yves
authors.initials: PY
authors.lastname: Boelle
authors.forename: Philippe
authors.initials: P
authors.lastname: Bonnard
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Molina
authors.forename: Patrick
authors.initials: P
authors.lastname: Miailhes
authors.forename: Caroline
authors.initials: C
authors.lastname: Lascoux-Combe
authors.forename: Lawrence
authors.initials: L
authors.lastname: Serfaty
authors.forename: Fabien
authors.initials: F
authors.lastname: Zoulim
authors.forename: Pierre-Marie
authors.initials: PM
authors.lastname: Girard
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004279:DNA, Viral / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000821:virology; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy / Q000821:virology; D006515:Hepatitis B virus / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000494:pharmacology / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D063065:Organophosphonates; C053001:adefovir; D000068698:Tenofovir; D000225:Adenine
references.citation: Gastroenterology. 2001 Mar;120(4):1009-22
references.pmid: 11231956
references.citation: N Engl J Med. 2003 Feb 27;348(9):808-16
references.pmid: 12606735
references.citation: J Viral Hepat. 2008 Feb;15(2):108-14
references.pmid: 18184193
references.citation: AIDS. 2005 Jun 10;19(9):907-15
references.pmid: 15905671
references.citation: J Hepatol. 2006 Jan;44(1):62-7
references.pmid: 16274835
references.citation: N Engl J Med. 2005 Jun 30;352(26):2682-95
references.pmid: 15987917
references.citation: Gut. 1989 Aug;30(8):1116-22
references.pmid: 2670693
references.citation: J Hepatol. 2006;44(1 Suppl):S90-4
references.pmid: 16352368
references.citation: Gut. 2010 Apr;59(4):513-20
references.pmid: 19736361
references.citation: Hepatology. 2006 Mar;43(3):548-55
references.pmid: 16496322
references.citation: AIDS. 2005 Mar 24;19(6):593-601
references.pmid: 15802978
references.citation: Hepatology. 2006 Nov;44(5):1110-6
references.pmid: 17058225
references.citation: J Hepatol. 1994 Oct;21(4):646-55
references.pmid: 7814812
references.citation: Gastroenterology. 2006 Dec;131(6):1743-51
references.pmid: 17087951
references.citation: Hepatology. 2004 Dec;40(6):1421-5
references.pmid: 15565615
references.citation: N Engl J Med. 2003 Jan 9;348(2):177-8
references.pmid: 12519935
references.citation: AIDS. 2006 Nov 14;20(17):2229-31
references.pmid: 17086064
references.citation: AIDS. 2006 Feb 14;20(3):419-27
references.pmid: 16439876
references.citation: J Clin Microbiol. 2006 Aug;44(8):2792-800
references.pmid: 16891494
references.citation: N Engl J Med. 2004 Sep 16;351(12):1206-17
references.pmid: 15371578
references.citation: AIDS. 2005 Nov 18;19(17):2036-8
references.pmid: 16260913
references.citation: Antivir Ther. 2006;11(6):771-8
references.pmid: 17310821
references.citation: Hepatology. 1996 Aug;24(2):289-93
references.pmid: 8690394
references.citation: Antimicrob Agents Chemother. 2002 May;46(5):1586-8
references.pmid: 11959607
references.citation: J Infect Dis. 1991 May;163(5):1138-40
references.pmid: 2019762
references.citation: Clin Infect Dis. 2004 Mar 1;38 Suppl 2:S65-72
references.pmid: 14986277
references.citation: Antivir Ther. 2007;12(2):279-83
references.pmid: 17503671
references.citation: J Viral Hepat. 2004 Mar;11(2):97-107
references.pmid: 14996343
references.citation: Hepatology. 2000 Jan;31(1):207-10
references.pmid: 10613747
references.citation: Hepatology. 1999 Nov;30(5):1302-6
references.pmid: 10534354
references.citation: N Engl J Med. 1998 Jul 9;339(2):61-8
references.pmid: 9654535
references.citation: J Clin Virol. 2006 May;36(1):60-3
references.pmid: 16418013
references.citation: Antivir Ther. 2006;11(6):669-79
references.pmid: 17310811
references.citation: Semin Liver Dis. 2003 Feb;23(1):21-38
references.pmid: 12616448
references.citation: N Engl J Med. 2003 Feb 27;348(9):800-7
references.pmid: 12606734
references.citation: Antivir Ther. 2005;10(6):727-34
references.pmid: 16218172
references.citation: Antivir Ther. 2004 Jun;9(3):353-63
references.pmid: 15259898
references.citation: AIDS. 2002 Jun 14;16(9):1257-63
references.pmid: 12045491
references.citation: Ann Intern Med. 2007 Dec 4;147(11):745-54
references.pmid: 17909201
references.citation: Hepatology. 2007 Dec;46(6):1695-703
references.pmid: 18027877
references.citation: Antimicrob Agents Chemother. 2006 Jul;50(7):2471-7
references.pmid: 16801428
references.citation: N Engl J Med. 2007 Dec 20;357(25):2576-88
references.pmid: 18094378